TABLE 2.
Inhibitory activities of CHR-derived peptides on HIV-1-mediated cell-cell fusion
| Peptide | Sequencea | Mean IC50 (nM) ± SD |
|---|---|---|
| CP613-644 | SWSNKSLEQIWNNMTWMEWDREINNYTSLIHS | 1,962.11 ± 29.72 |
| CP618-649 | SLEQIWNNMTWMEWDREINNYTSLIHSLIEES | 86.94 ± 1.63 |
| CP621-652 | QIWNNMTWMEWDREINNYTSLIHSLIEESQNQ | 4.23 ± 0.35 |
| CP623-654 | WNNMTWMEWDREINNYTSLIHSLIEESQNQQE | 70.22 ± 1.18 |
| CP628-654 | WMEWDREINNYTSLIHSLIEESQNQQE | >4,000.00 |
| C34 | WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL | 3.65 ± 0.39 |
| T20 | YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF | 26.43 ± 0.94 |
a
The residue numbers of each region corresponds to their positions in gp160 of HIV-1HXB2. The residues forming the PBD are in boldface type, and the residues preceding the PBD are in italic type.